Table 2.
Frequency SIRT1 overexpression in colorectal cancer according to various molecular features
| Molecular feature | Total N | SIRT1+ | Odds ratio (95% confidence interval) |
P value | |
|---|---|---|---|---|---|
| CIMP status (No. of methylated CIMP markers) |
|||||
| CIMP-0 (0) | 209 | 76 (36%) | 1 | Referent | |
| CIMP-low (1–5) | 187 | 58 (31%) | 1.27 (0.84–1.93) | ||
| CIMP-high (6–8) | 74 | 42 (57%) | 2.30 (1.34–3.94) | 0.002 | |
| MSI status | |||||
| MSS | 345 | 117 (34%) | 1 | Referent | |
| MSI-low | 55 | 14 (25%) | 1.50 (0.79–2.87) | ||
| MSI-high | 83 | 49 (59%) | 2.81 (1.72–4.59) | <0.0001 | |
| CIMP and MSI status | |||||
| CIMP-low/0 MSI-low/MSS | 367 | 121 (33%) | 1 | Referent | |
| CIMP-high MSI-low/MSS | 22 | 7 (32%) | 0.95 (0.38–2.39) | ||
| CIMP-low/0 MSI-high | 28 | 13 (46%) | 1.76 (0.81–3.82) | ||
| CIMP-high MSI-high | 52 | 35 (67%) | 4.19 (2.25–7.77) | <0.0001 | |
| BRAF mutation | |||||
| (−) | 404 | 143 (35%) | 1 | ||
| (+) | 68 | 31 (46%) | 1.53 (0.91–2.57) | ||
| KRAS mutation | |||||
| (−) | 310 | 120 (39%) | 1 | ||
| (+) | 173 | 59 (34%) | 0.82 (0.56–1.21) | ||
| PIK3CA mutation | |||||
| (−) | 374 | 137 (37%) | 1 | ||
| (+) | 57 | 23 (40%) | 1.17 (0.66–2.07) | ||
| LINE-1 methylation | |||||
| ≥70% | 58 | 22 (38%) | 1 | ||
| 60–70% | 155 | 61 (39%) | 1.06 (0.57–1.98) | ||
| 50–60% | 184 | 72 (39%) | 1.05 (0.57–1.93) | ||
| <50% | 66 | 20 (30%) | 0.71 (0.34–1.50) | ||
| p53* | |||||
| (−) | 285 | 110 (39%) | 1 | ||
| (+) | 197 | 69 (35%) | 0.86 (0.59–1.25) | ||
| Nuclear β-catenin* | |||||
| (−) | 269 | 104 (39%) | 1 | ||
| (+) | 166 | 68 (41%) | 1.10 (0.74–1.63) | ||
| FASN (fatty acid synthase)* | |||||
| (−) | 427 | 149 (35%) | 1 | Referent | |
| (+) | 52 | 28 (54%) | 2.18 (1.22–3.89) | 0.008 | |
| COX-2 (cyclooxygenase-2)* | |||||
| (−) | 92 | 32 (35%) | 1 | ||
| (+) | 391 | 147 (38%) | 1.13 (0.70–1.82) | ||
Only significant p values are described.
*
p53, β-catenin, COX-2 and FASN were assessed by immunohistochemistry.